For the quarter ended September 2025, Zimmer Biomet (ZBH) reported revenue of $2 billion, up 9.7% over the same period last year. EPS came in at $1.90, compared to $1.74 in the year-ago quarter.
The reported revenue represents a surprise of -0.42% over the Zacks Consensus Estimate of $2.01 billion. With the consensus EPS estimate being $1.88, the EPS surprise was +1.06%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Zimmer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Knees- United States: $440.1 million versus the four-analyst average estimate of $443.24 million. The reported number represents a year-over-year change of +3.5%.
- Net Sales- Hips- United States: $264.7 million versus $265.2 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4% change.
- Net Sales- Hips- International: $241.5 million versus $244.82 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.4% change.
- Net Sales- Knees- International: $352.3 million versus $347.08 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +10.2% change.
- Net Sales- International: $837.3 million compared to the $850.8 million average estimate based on three analysts. The reported number represents a change of +8.5% year over year.
- Net Sales- United States: $1.16 billion versus $1.15 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.6% change.
- Net Sales- Knees: $792.4 million versus the seven-analyst average estimate of $788.1 million. The reported number represents a year-over-year change of +6.4%.
- Net Sales- Technology & Data, Bone Cement and Surgical: $161.3 million compared to the $160.61 million average estimate based on seven analysts.
- Net Sales- S.E.T: $541.5 million versus $552.12 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +19.2% change.
- Net Sales- Hips: $506.2 million compared to the $508.21 million average estimate based on seven analysts. The reported number represents a change of +5.1% year over year.
View all Key Company Metrics for Zimmer here>>>
Shares of Zimmer have returned +4.2% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
